VR Adviser
ATYR icon

VR Adviser’s aTyr Pharma ATYR Stock Holding History

VR Adviser’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-29,286
Closed -$2.57M – 29
2022
Q4 		$2.57M Sell
29,286
-5,686
-16% -$536K 0.43% 26
2022
Q3 		$4.2M Hold
34,972
– – 0.65% 28
2022
Q2 		$3.96M Hold
34,972
– – 0.78% 24
2022
Q1 		$7.48M Sell
34,972
-4,153
-11% -$941K 1.21% 20
2021
Q4 		$11.7M Hold
39,125
– – 1.6% 19
2021
Q3 		$14.2M Buy
+39,125
New +$9.36M 1.83% 18

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Stonepine Capital Management
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Samsara BioCapital
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
CVI Holdings
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser's ATYR Position: Q1 2023 in Review

VR Adviser sold out of aTyr Pharma (ATYR) in Q1 2023, closing a stake of 29,286 shares — an estimated $2.57M sold.

VR Adviser first reported a position in ATYR in Q3 2021 and held it in 6 quarters. The position peaked at $14.2M in Q3 2021. 36 funds tracked by Wall St. Rank hold ATYR as of Q1 2023.

  • VR Adviser reported no remaining aTyr Pharma position as of Q1 2023 after selling out during the quarter.
  • VR Adviser sold 29,286 aTyr Pharma shares in Q1 2023, an estimated $2.57M.
  • VR Adviser first reported a position in aTyr Pharma in Q3 2021 and held it in 6 quarters.
  • VR Adviser's aTyr Pharma position peaked at $14.2M in Q3 2021.
  • 36 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2023.

Based on VR Adviser's 13F filing for Q1 2023, filed 15 May 2023.